Trajan acquires HDExaminer Software from California-based, Sierra Analytics Inc.

February 15, 2023

Trajan Scientific and Medical announces the completion to acquire specialized software business, HDExaminer, from California-based, Sierra Analytics, Inc.

HDExaminer is used in Hydrogen Deuterium Exchange Mass Spectrometry (HDX-MS), which is a powerful technique providing insight into protein dynamics. HDX-MS studies can be used to connect structure, behaviour, and function of a protein, between proteins and drugs, development of life-saving vaccines, as well as the cause and potential resolution of protein misfolding diseases.

Trajan has become a global leader in the automation of the HDX-MS technique and has also been the exclusive distributor of the HDExaminer since early 2018. HDExaminer enables the analysis of the protein structural information generated by the Mass Spectrometer.

Stephen Tomisich, Trajan CEO said “bringing ownership of HDExaminer into the Trajan family allows us to invest in the future development and enhancement of this powerful analytical platform. Together with our growing number of leading collaborators in the field of HDX-MS we expect to target several areas of the package to enable broader adoption of the technique along with enhancing the depth and value of protein structural information that can be revealed.”

Also in News

Trajan collaborates with Monash University for the development of HDX training centre

February 03, 2023

Trajan Scientific and Medical with Monash University would like to announce a collaboration for the development of an HDX training centre at Monash University's Proteomics and Metabolomics Facility (MPMF). This collaboration will provide the university with access to a Trajan HDX system and allow Trajan to provide HDX training to the proteomics community in the region.

Baker Institute research leads to simple tests for heart and diabetes disease

January 13, 2023

Collaboration has been key to a global health innovation to counter cardiovascular disease. One of Australia’s leading research facilities, the Baker Heart and Diabetes Institute, had the technology to potentially revolutionise testing for heart disease and diabetes, using just a single drop of blood. All it lacked for this global breakthrough was commercial nous, developmental infrastructure and marketing know-how. On the other hand, Trajan Scientific and Medical, a Melbourne-based ASX biotech company, had the technology and expertise to take products to market.

Trajan Scientific and Medical to license the Baker Institute’s lipidomic analysis methodology and metabolic risk scores algorithms.

October 10, 2022

Trajan Scientific and Medical, and the Baker Heart and Diabetes Institute, have reached an in-principle understanding for Trajan to license the Baker Institute’s lipidomic analysis methodology and metabolic risk scores algorithms.